Form 4 for ARQT Arcutis Biotherapeutics, Inc.
Accepted 2023-02-21 00:00:00 ET · period of report 2023-02-15 · accession 0001787306-23-000010 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-02-21 | 2023-02-15 | ARQT | Welgus Howard G. | Dir | M - OptEx | $1.68 | +8,500 | 174.3K | +5% | +$14.3K |
| D | 2023-02-21 | 2023-02-15 | ARQT | Welgus Howard G. | Dir | S - Sale+OE | $16.98 | -8,500 | 165.8K | -5% | -$144.3K |
| D | 2023-02-21 | 2023-02-15 | ARQT | Welgus Howard G. | Dir | M - OptEx | $0.00 | -8,500 | 23.5K | -27% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-02-15 | M | A | 8,500 | $1.68 | 174,325 | D | — | — | |
| 2 | Common | Common Stock | 2023-02-15 | S | D | 8,500 | $16.98 | 165,825 | D | — | — | (F2) The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $16.84 to $17.10, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| 3 | Derivative | Stock Option (right to buy) | 2023-02-15 | M | D | 8,500 | $0.00 | 23,458 | D | $1.68 · — to 2029-03-13 | 8,500 Common Stock | (F4) The option began vesting on March 13, 2019 and will vest monthly over a four year period, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. |